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Hearing loss is the most common symptom in patients with vestibular schwannoma (VS). In the past, compressive mechanisms
caused by the tumoral mass and its growth have been regarded as the most likely causes of the hearing loss associated with
VS. Interestingly, new evidence proposes molecular mechanisms as an explanation for such hearing loss. Among the molecular
mechanisms proposed are methylation of TP73, negative expression of cyclin D1, expression of B7-H1, increased expression of the
platelet-derived growth factor A, underexpression of PEX5L, RAD54B, and PSMAL, and overexpression of CEA. Many molecular
mechanisms are involved in vestibular schwannoma development; we review some of these mechanisms with special emphasis on
hearing loss associated with vestibular schwannoma.
1.Introduction
Vestibular schwannomas (VSs) can be classiﬁed into two
broad groups: unilateral sporadic vestibular schwannoma
and those associated with neuroﬁbromatosis type 2 (NF2).
VSs constitute 8% of all benign intracranial tumors, and
sporadic unilateral schwannomas represent up to 95% of all
VSs [1]. As new population-based studies are performed, the
true incidence of VS appears to be higher than expected [2–
5]. A nationwide study performed in Denmark [2] revealed
that the incidence of VS had been rising from 5 cases per
million population per year in 1977–1981 to 10 cases in
1992–1995. In 2004, the same research group estimated an
incidence of 11.5 cases per million inhabitants per year
during a 25-year period (1976–2001) [3]. Data from a US
national tumor registry (2010) reported a VS incidence rate
of 1.1 cases per 100,000 people per year [4]. On the other
hand, Evans et al. found an incidence of 1 case in 80,000
individuals for sporadic VS, and 1 in 70,000 if NF2-related
tumors were included [5]. These increasing numbers are
probably due to the eﬀe c to fn e w e ra n dm o r es e n s i t i v ed i a g -
nostic tests, especially magnetic resonance imaging (MRI).
The age of presentation of VS is usually the fourth and ﬁfth
decades. Even though a benign tumor, if large enough, can
cause neurological symptoms like hydrocephalus, brainstem
compression, herniation, and ultimately death.
NF2 is an autosomal dominant disease representing 5%
of all VSs. Patients with NF2 are characterized by having
bilateral vestibular schwannomas. Half of these patients do
not have a family history of the disease [1] and therefore
represent new germline mutations. The Manchester criteria
for the diagnosis of NF2 have been described elsewhere
[6, 7]. These patients can also present other intracranial
benign tumors. There are three types of NF2, distinguished
according to clinical presentation and severity: Wishart type,
Gardner type, and mosaic NF2. The Wishart type appears
in childhood or late adolescence and consists of bilateral
vestibular schwannomas associated with spinal tumors. The2 Genetics Research International
Gardnertype appearslaterin lifeand is less debilitating, with
patients developing bilateral vestibular schwannomas but
few meningiomas. Mosaic NF2 occurs when a postzygotic
mutation takes place and only a portion of the cells carry
this mutation. Around 25% of NF2 patients with apparently
healthy parents have a mosaicism [8].
Schwannomatosis has been recently deﬁned as a new
form of neuroﬁbromatosis. It consists of multiple schwan-
nomas without associated vestibular schwannomas [1]. The
main symptom of aﬀected patients is pain. The SMARCB1
gene has been found to be mutated in schwannomatosis
patients [9–12]. SMARCB1, located in chromosome band
22q11.2 [9–12], is a tumor suppressor gene that encodes
the INI1 protein. Germline mutations have been described
in both familial [10–12] and sporadic [9, 11, 12]c a s e s
of schwannomatosis. Immunohistochemical analysis of VS
samples [12] detected a mosaic pattern of INI1 expression in
93% of familial schwannomatosis patients, 55% of sporadic
schwannomatosis cases, 83% of NF2-associated tumors, and
5%ofsolitarysporadicschwannomas.Theseﬁndingssuggest
thattheSMARCB1genemightalsoplayaroleinNF2tumors
[12].
It is estimated that 80% of patients with VS initially
complain of hearing loss or tinnitus. Such hearing loss
could be the result of various mechanisms [13]. Among
them are direct compression of the cochlear nerve by the
tumor; occlusion or vascular compression of the internal
auditory artery; intratumoral bleeding; biochemical changes
in the inner ear, caused by vascular compression or internal
auditory canal occlusion. Another cause that has emerged
as an interesting possible explanation of this symptom
relates to molecular data. Some authors [13, 14]s u g g e s t
that a degeneration of the inner ear may be caused by a
toxic substance produced by the tumor, or by a deﬁciency
in a factor that is crucial for proper inner ear function.
Dissociation between tumor size and hearing loss has been
described elsewhere [13, 15]a n dc o u l db ea no b j e c t i o nt o
the theory that compression is the sole cause of hearing loss.
Newwaystoexplaindeteriorationofhearinginpatientswith
VS are needed.
The molecular biology of VS has been explained by
several pathogenic mechanisms including NF2 gene muta-
tion [1, 16, 17], chromosome 22 loss [16–20], NF2 gene
mitotic recombination [18, 20], DNA methylation [21, 22],
deregulation of genes [23], immunogenic factors [24, 25],
cytokines, and growth factors [26–30]. Early data on the
genetic alterations of VS were provided by cytogenetic
studies [31–37]. Monosomy 22 was identiﬁed in various
types of schwannomas, including VS. The incidence of total
loss of chromosome 22 varies among VS studies and can
reach 50% [31–37]. Other chromosome changes have been
observed rarely, and, although these variations do not show
a consistent pattern, losses of chromosomes 14, 16, 17, 18,
and Y have been observed in at least one sample [31–
37]. Warren et al. [38] studied 76 vestibular schwannoma
samples, ﬁnding that 10% of the tumors showed copy gains
in chromosome 9q34. Three tumors had gains in 17q,
and, in three or fewer tumors, copy gains and copy losses
were identiﬁed in chromosomes 10, 11, 13, 16, 19, X, and
Table 1: Molecular mechanisms described in VS growth.
NF2 gene mutation
Loss of chromosome 22
NF2 gene mitotic recombination
DNA methylation
Deregulation of genes
Immune response alteration
Growth factors and cytokines
Y. The relevance of copy gains in chromosome 9 is still
under investigation. In parallel, loss of heterozygosity (LOH)
studies have demonstrated that deletions of chromosome
22 have occurred in up to 80% of schwannomas, including
VS cases. These ﬁndings suggest that genes located on this
chromosome play an essential role in VS development [39–
41].Alleliclossesat1phavealsobeendescribedinafewcases
[42]. Mitotic recombination consists of deletion followed by
reduplication. This mutational mechanism can generate two
identical copies of a mutated gene in the absence of a wild-
type copy [17]. This mechanism is responsible for LOH in a
proportion of schwannoma cases [18, 20] (see Table 1).
2. NF2 Gene
The molecular study of VS began in 1993 with the iden-
tiﬁcation of the NF2 gene which contains 17 exons and
is located in chromosome 22q12.2 [43, 44]. The coding
region of messenger RNA is 1785 base pairs in length and
encodes 595 amino acids, producing a protein named merlin
(for “moesin-ezrin-radixin-like protein”) or schwannomin
(derivedfromschwannoma).Thisfamilyofproteinspresents
an N-terminal globular domain (FERM domain), an α-
helical stretch, and a charged C terminus at the end [1, 16].
It is believed that this protein acts by linking the actin
cytoskeleton to the plasma membrane. Merlin has the ability
to change its conformation status. It can fold into itself
(closed conformation) or be unfolded (open conformation).
This can be achieved by folding its alpha helical portion
and c-terminal portion [45]. P21-activated kinase 1 (PAK), a
downstream eﬀector of Rac1, promotes the phosphorylation
of merlin at S518 with conversion to an open conformation,
initiating its degradation [46]. The folded form of merlin
is known for its tumor-suppressing properties [47]. The
folded version of merlin binds to DCAF1 and suppresses
cell proliferation by inhibiting E3 ubiquitin ligase CRL4
[48]. CRL4DCAF1 plays a role in DNA replication and, if
inactivated by merlin, favors the upregulation of genes
related to apoptosis and cell-cycle arrest [48].
Rac1isamemberoftheRhoGTPasefamilyandregulates
signaling pathways such as MAPK, JNK/SAPK, NF-kβ,a n d
PI-3K [49, 50]. Rac1 is associated with tumorigenesis [50].
Merlin downregulates Rac1-mediated canonical Wnt signal-
ing, becoming a negative feedback loop preventing Rac1
activation and therefore phosphorylation by PAK [51–53].
There is an association between Merlin, CD44, and β1-
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implicated in cell-cell adhesion, cell matrix adhesion, cell
motility, and metastasis [1]. Herrlich et al. [54]d e m o n -
strated that at high cell density, hypophosphorylation of
merlin occurs, which inhibits cell growth. On the other
hand, at low cell density, phosphorylation of merlin occurs,
becoming growth permissive. In both scenarios, merlin
interacts with CD44, promoting cellular contact-dependent
inhibition.
The NF2 gene has been shown to be a tumor suppressor
gene. This was evident in mouse models, where overexpres-
sion of the NF2 gene (merlin) has been proven to limit
cell growth in mouse ﬁbroblast and rat schwannoma cells
[55, 56].
In various studies, epidermal growth factor (EGF) and
epidermal growth factor receptor B (ErbB2) are upregulated
in VS cells [57, 58]. Merlin’s proliferative activity depends
on the regulation of these factors. Neuroglin induces prolif-
eration of VS cells by binding to ERbB2 and ERbB3 [58],
as subsequent activation of PI3K and MAPK (mitogen-
activatedproteinkinase)pathwaysoccurs.Bothpathwaysare
associated with cellular invasion [27]. MAPK is regulated
by mitogen stimuli mixed lineage kinase 3 (MLK3). Finally,
merlin has been shown to inhibit MLK3 and epidermal
growth factors, demonstrating its tumor suppressive prop-
erties [59].
These molecular and signaling pathways can help us to
understand new therapies for VS treatment, some of which
will be discussed further below.
3. Mutations of the NF2 Gene,
DNA Methylation,andHearingLoss
Mutations of the NF2 gene have been found in both
NF2 and unilateral sporadic schwannoma patients. More
than 200 mutations have been identiﬁed to date, including
single-base substitutions, insertions, missense, and deletions
[60]. NF2 gene inactivation is necessary for VS to grow.
According to Knudsen’s two-hit hypothesis, in NF2 patients,
thegermlineNF2alleleisinactivatedandtumorsoccurwhen
a wild-type allele is inactivated by allelic loss, silencing, or
mutation [17]. On the other hand, sporadic unilateral VS
formation is explained by somatic biallelic NF2 inactivation
[17]. Regarding the eﬀect of age on unilateral sporadic
VS formation, Evans et al. [61] have hypothesized that
new somatic mutations are added to the NF2 gene due
to impaired DNA repair mechanisms. They also found an
increased ratio of somatic frameshift to nonsense mutations
with increased age at diagnosis.
Hadﬁeld et al. [20] identiﬁed germline mutations in 89%
ofasampleof97patientswithanNF2diagnosisandasecond
mutational event in 79% of the sample. LOH was the most
common form of second hit. Mitotic recombination was the
cause of LOH in 14 out of 72 total evaluable NF2 tumours.
Ontheotherhand,inasampleof104patientswithunilateral
sporadic VS, 66% had at least one somatic point mutation
identiﬁed by MLPA (Multiplex ligation dependent probe
ampliﬁcation), loss of heterozygosity (LOH) was found in
56%, and mitotic recombination was a cause of LOH in 6%.
The genotype-phenotype correlation in NF2 patients
has been studied. While some authors deny any correlation
[1,62],othersaﬃrmit[63,64].Recentevidencehasdetected
genotype-phenotype correlation in NF2 patients [65–68].
The Manchester group [65] studied 411 NF2 patients and
correlated the presence of meningiomas with gene muta-
tions. Interestingly, they did a genotype-phenotype correla-
tion based not only on the type of mutation but also on the
position eﬀect of the mutation itself. Patients with mutations
in exons 14 or 15 develop meningiomas less frequently; in
other words, patients with mutations located in exons 1 to
13 had a higher risk of developing meningiomas. Regarding
the type of mutation, it was observed that individuals with
truncating mutations (nonsense or frameshift) had a higher
risk of meningiomas than patients with missense or splicing
mutations (58% versus 26% versus 35%, resp.). This ﬁnding
had already been described by Selvanathan et al. [66]a n d
Evans et al. [67], where nonsense and frameshift mutations
were associated with more severe NF2 symptoms.
Abo-Dalo et al. [68] demonstrated that clinical features
in individuals with large intragenic deletions were similar
to those in individuals with mutations aﬀecting single or
multiplenucleotides.Milderphenotypewasseenindeletions
aﬀecting 3 exons 15 and 16 of the NF2 gene, corroborating
thesameﬁndingofSmithetal.,wheremutationpositionwas
fundamental in phenotype expression.
Currently, thereisanewunderstanding oftheroleplayed
by the type and position of NF2 mutations in the phenotype
ofthedisease. Nevertheless,it hasbeenreportedthat families
andidenticaltwinswithNF2carryingthesamemutationcan
develop diﬀerent phenotypes [69, 70].
Besides the type and position of the mutation [71], there
are other possible mechanisms that can explain NF2 inac-
tivation [1]. Presence of a modiﬁer gene [72], methylation
of the regulatory region [21, 22, 73], posttranscriptional
alternative splicing, and diﬀerential polyadenylation of the
NF2 gene [74] are proposed as possible causes. On the other
hand, the NF2 gene promoter area is a region of DNA that
facilitates transcription. Welling et al. [75] described how
methylation of the regulatory region of the NF2 gene occurs.
Both positive and negative cis-acting regulatory elements
required for transcription of the NF2 gene have been found
on the 5  ﬂanking region of the promoter. This region is rich
in G/C and susceptible to inactivation and methylation.
Robertson [76] covered the DNA methylation process
extensively, deﬁning it as a crucial epigenetic modiﬁca-
tion of the genome that is involved in regulating many
cellular processes, including transcription. This epigenetic
modiﬁcation of DNA consists of methylation of cytosine at
position C5 in CpG dinucleotides. CpG islands are generally
unmethylated. It has been claimed that DNA methylation
represses transcription directly, by inhibiting the binding
of transcription factors, or indirectly, by recruiting methyl-
CpG-binding proteins. Hypermethylation of the promoter-
associated CpG islands leads to transcriptional silencing
and ﬁnally to epigenetic inactivation of tumor suppressor
genes [21]. The DNA methylation of VS has not been fully
studied. Data on the methylation status of the promoter
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[77]. Only 10% of schwannoma cases displayed this DNA
modiﬁcation. Kino et al. [73] found methylation of 3 CpG
islands in 14 of 23 VS patients. Gonzalez-Gomez et al.
[22] and Bello et al. [78] identiﬁed the 5 tumor-related
genes most frequently methylated in VS cases (THBS1,
TP73,MGMT,NF2, andTIMP3).Thesetumor-related genes
were chosen on the basis of their critical cancer-related
functions, since they are frequently hypermethylated and
silenced in other neoplasms. Among their known functions
aretumorsuppression,angiogenesisandinvasioninhibition,
DNArepair,anddetoxiﬁcation.NF2genepromoterelements
showed hypermethylation in 18% of cases, which suggests
analternativemechanismofNF2geneinactivation.Aberrant
methylation of the NF2 gene could be considered a relatively
early event, whereas hypermethylation of other tumor-
related genes might represent secondary changes [22]. These
results were demonstrated to be speciﬁcally due to negativity
on control tissues (nonneoplastic nerve sheath and brain
samples).
To understand the role of TP73 (located at 1p36.3), we
have to be aware of its homology, in terms of structure and
conformation, with TP53 (located at 17p13.1). Both genes
are involved in apoptosis and inhibition of cell growth. It
has been proposed that p53 haploinsuﬃciency has a role in
the development of VS [79]. TP73 null mice show speciﬁc
developmental defects but no spontaneous tumors, giving
rise to multiple protein isoforms with opposite biological
properties [80]. Ahmad et al. [79] stated that p73 can
produce multiple protein isoforms generated by alternative
promoters and alternative splicing. Overexpression of p73
in various carcinomas correlates with poor prognosis [80].
Allart et al. [81] suggested that TP73 plays a major role
in cellular diﬀerentiation and apoptosis in neuronal tissues.
Ahmad et al. [79] conﬁrmed this in their study of 34
VS tissues, which found expression of p73 in 41% of
the specimens. Furthermore, after transfecting experimental
vestibular schwann cells with p73 plasmid and exposing
them to ionizing radiation, an increase in early apoptosis,
late apoptosis, and necrosis was observed, as compared to a
control group.
Lassalettaetal.[21]exploredthemethylationstatusof16
tumor-related genes in 22 unilateral VSs. DNA methylation
values of 9 to 27% were found in 12 of the genes tested:
RASSF1A, VHL, PTEN, TP16, CASP8, TIMP3, MGMT,
DAPK, THBS1, HMLH1, TP73, and GSTP1. The association
discovered between TP73 aberrant methylation and hearing
loss was remarkable. The corrected hearing thresholds for
patients with methylated and unmethylated TP73 genes were
43dBand17dB,respectively(P = 0.04).Thefrequencymost
aﬀected was 1000Hz.
Additionally, Lassalettaet al. [21] found that methylation
ofTP73hadnoassociationwithage,clinicalgrowthindex,or
tumor size. Other clinical ﬁndings concerning tumor-related
genes included an association of methylation of CASP8
with age and tumor size and an inverse correlation between
RASSF1A methylation and clinical growth index.
The scientiﬁc relevance of methylation to hearing loss
needs further study, as, at present, methylation of TP73 is the
only mechanism implied in hearing loss pathogenesis [6].
Figure 1: Positive immunostaining (+++) for cyclin D1.
4. DeregulatedGenesin
Vestibular Schwannoma
Molecular studies are based on the gene expression of
tumors. According to new data [1, 19, 82, 83], it is now
possible to diﬀerentiate one tumor from another in ways
unavailable to histopathology. Molecular investigation also
suggests that mutations alone cannot explain the diverse
behavior of VS. Welling et al. [82] studied 7 vestibular
schwannomas by microarray DNA analysis, concluding
that 42 genes were signiﬁcantly upregulated in six of
seven tumors studied. Among the upregulated genes were
mediators of angiogenesis like endoglin (an endothelial
marker of angiogenesis) and osteonectin (a promoter of
cellmigration).Downregulatedgenesincludedanapoptosis-
related putative tumor suppressor gene, LUCA-15. The
retinoblastoma protein (pRb) is encoded by the RB1 gene.
Lasak et al. [84] examined a deregulated signaling pathway,
the retinoblastoma protein (pRb)-cyclin-dependent kinase
(CDK) pathway, which was downregulated in 7 of 8 tumors.
This signaling pathway is involved in the G1 to S cell
cycle progression, promoting cell proliferation. As already
stated by Cay´ e-Thomasen et al. [23], the available data for
the CDK pathway is conﬂicting, since one group found
downregulation [84] while the other found upregulation
[23]. Gonzalez-Gomez et al. [22] had previously suggested
an inverse link between the methylation of RB1 and p16INK4a
(found in 15% of samples) and cell cycle regulation, with the
latter being altered through epigenetic changes. This in turn
may explain the RB1-CDK pathway deregulation [84].
Deregulatedexpressionofgrowthregulatorygenesmight
play a role in VS progression. Cyclin D1 is a cell-cycle
regulatory protein for the mammalian G1-S phase transition
and is implicated in cell proliferation and diﬀerentiation.
Lassaletta et al. [85] found, using immunohistochemistry,
cyclin D1 expression in 52% of their cases. This deregulated
gene was more frequently present in tumors with nuclear
degenerativechanges(Figure 1).Patientswithnegativecyclin
D1 expression had a longer duration of deafness (P = 0.02)
and higher 2,000Hz hearing thresholds (P = 0.04) than
cyclinpositive patients.Inspiteoftheneedformoreresearch
to fully understand these results, this is the only study that
hasmadeacorrelationbetweenclinicalsymptoms andcyclin
deregulation.Genetics Research International 5
By contrast, in a 2006 study, Neﬀ et al. [86]f o u n d
no staining of cyclin D1 in 15 VS specimens. Stankovic et
al. [14] collected VS surgical specimens from 13 patients
and classiﬁed them into two groups, one with good
hearing (word recognition >70% and pure tone aver-
age ≤30dB) and another with poor hearing. The entire
genomeexpressionwastestedbymicroarraytechnology.The
expression of selected genes was validated using real-time
quantitative reverse transcription-polymerase chain reaction
and immunohistochemistry. A chromosomal region (3q27)
was found to be expressed diﬀerently in the two groups
of patients. The peroxisomal biogenic factor 5-like gene
(PEX5L), a gene within this chromosomal region with a
recognized role in hearing, was found to have underexpres-
sion in VS patients with poor hearing. Another 3 genes were
foundtobeunderexpressedinVSpatientswithpoorhearing:
RAD54, homolog B (RAD54B), and the prostate-speciﬁc
membrane antigen-like gene. In contrast, carcinoembryonic
antigen was highly expressed. The negative results were also
of interest: no correlation was found between the presence
of axons and preservation of hearing, nor between vessel
density and hearing loss. Finally, no signiﬁcant diﬀerences in
platelet-derived factor 4 expression were found between the
groups.
Stankovic et al. [14] also explained each of their
positive results and their possible roles in hearing loss.
PEX5L, located in the chromosomal region 3q27, is gen-
erally expressed in brain tissue, and it is linked to the
regulation of peroxisomal protein import. It is believed
that peroxisomal dysfunction could aggravate hearing loss
in patients with VS, due to underexpression of PEX5L.
The authors suggest pathologic accumulation of fat and/or
demyelination and neurodegeneration of the acoustic nerve
as possible mechanisms of such hearing loss. They argue that
hereditary demyelinating disease or peroxisomal disorders
manifest with sensorineural hearing loss similar to that of
VS. Moreover, histopathology has also shown demyelinating
changes in the nearby vestibular nerve. All of these factors
oﬀer support for the theory of peroxisomal dysfunction.
RAD54B is another gene that is underexpressed in
patients with VS and poor hearing [14]. This gene has been
associated with the recombinational repair of DNA damage.
Stankovic et al. found a nuclear distribution of RAD54B in
VS patients with poor hearing and cytoplasmic distribution
of this same gene in the good hearing group. The authors
suggest this may be due to diﬀerent ways of responding to
DNA damage. Nonetheless, a question still remains: how
does an impaired ability to repair DNA in VS patients
contribute to hearing loss? Mutations in RAD54B have also
beenidentiﬁedinnon-Hodgkinlymphomaandcoloncancer
[87], and their relationship to VS development must be fully
determined.
PSMAL (glutamate carboxypeptidase III) also showed
lower levels of expression in the group with VS and poor
hearing [14]. This gene has been reported to have a high
expression in brain tissue. Unfortunately, its biological
implications for VS remain unknown. On the other hand,
the CEA-CAM7 gene and CEA protein had high expressions
inVSpatientswithpoorhearing.Thisdiﬀersfromtheoverall
results, in which underexpression was the rule. Likewise,
high levels of CEA in the cerebrospinal ﬂuid (CSF) have
been associated with benign and malignant tumors of the
central nervous system (CNS), and it has been proposed that
they are also associated with hearing loss [88]. Recently, a
newmammalianprotein,amemberofthecarcinoembryonic
antigen-related cell adhesion molecule (CEACAM), has been
identiﬁed [89]. CEACAM16mRNA is expressed in outer
hair cells, and its product localizes to the tips of the tallest
stereocilia and the tectorial membrane. According to Zheng
etal. [89], this localization might imply a role in maintaining
the integrity of the tectorial membrane as well as the
connection between the outer hair cell stereocilia and the
tectorial membrane, which is essential for mechanical sound
ampliﬁcation.Furthermore,amutationinCEACAM16leads
to autosomal dominant nonsyndromic deafness. These data
could clarify the relationship between CEA and hearing loss.
Again, more studies in this area are needed.
Stankovic et al. [14] also found a possible link between
CEA levels and peroxisomal dysfunction. The authors
explained that the activation of the nuclear hormone
peroxisome proliferator-activated receptor gamma induces
CEA. RAD54B and PSMAL could play an indirect role
in the degeneration of the inner ear. According to these
authors, this role might be a decrease in the production or
responsiveness required for normal auditory nerve and inner
ear function.
Using microarray gene expression technology, Lassaletta
et al. [90] studied tumor samples surgically removed from
11 patients with unilateral vestibular schwannomas. The
expression of platelet-derived growth factor A (PDGFA) was
inversely correlated with hearing loss (rs =− 0.942, P<
0.001). Mean PDGFA expression for tumor patients with
<40dB and ≥40dB pure tone threshold was 0.73 and 0.56,
respectively. PDGFs are mitogenic factors for smooth muscle
cells and also act as paracrine growth factors that medi-
ate epithelial-mesenchymal interactions in various tissues.
Increasingevidencesuggeststheymayhavearoleinsignaling
pathways with a tumor angiogenesis eﬀect. There are 4
members of PDGF (A, B, C, and D), and these bind to two
tyrosine kinase receptors that are speciﬁc to each member.
PDGF A, B, and C bind to PDGFRα, and PDGFB and D bind
to PDGFRβ. Ultimately, activation of these pathways leads to
cellular responses such as proliferation and migration. The
authors had no explanation for the relation between hearing
loss and PDGF.
5. Immune Response, Vestibular Schwannomas,
andHearing Loss
The literature contains studies of the immunogenic potential
of tumors and recently that of the vestibular schwannomas.
Rossi et al. [91] described the presence of macrophages,
CD8 and CD4 lymphocytes, in VS. Leukocyte migration
inhibition has been measured in serum, CSF, and perilymph
in VS patients [92]. Archibald et al. [24] proposed that B7
homolog 1 (B7-H1) was a protein aberrantly expressed in
malignant tumors (renal, breast, lung, and head and neck6 Genetics Research International
cancer) and also in VS. It is reported that B7-H1 acts as a
ligand that interacts with its counterreceptor, programmed
death-1 (PD-1) on activated T cells, inducing apoptosis and
inhibiting their proliferation and cytokine production. As
a consequence, there is a diminished immune response to
tumor cells and unrestricted growth. Archibald et al. [24]
studied 48 VS samples and correlated them with clinical data
and with immunohistochemical staining of B7-H1. Patients
with failure of tumor control after stereotactic radiation
therapy were signiﬁcantly more positive (P = 0.029) in
B7-H1 staining. This ﬁnding suggests a role for B7-H1 in
immune evasion and might explain the continued growth
of VS despite radiotherapy. Additionally, patients with worse
hearing at the moment of surgery tended to stain more
stronglyforB7-H1thanthebetterhearingpatients,although
no signiﬁcant diﬀerence between both groups was found.
6. CytokinesandGrowth Factors
Identiﬁcation of growth factors implied in VS progression
can provide new treatment options. Diﬀerent authors have
studied Ki67, proliferation cell nuclear antigens, nerve
growthfactorreceptors,transforminggrowthfactors,ﬁbrob-
last growth factors, interleukin 6, and hormones [25–30].
Nonetheless, these tumor growth factors have not been
identiﬁed as independent causes of hearing loss.
Vascular endothelial growth factors (VEGFs), on the
other hand, are associated with hearing loss and are
highly expressed in vestibular schwannoma [93–95]. Cay´ e-
Thomasenetal.[94]demonstratedacorrelationbetweenthe
concentration of vascular endothelial growth factors in VS
samples and rate of tumor growth. Plotkin et al. [95]f o u n d
VEGF expressed in 100% of 21 NF2-related schwannomas
and22sporadicschwannomasamples.Moreover,theyfound
hearingimprovementin4of7patientsundertreatmentwith
Bevacizumab. Bevacizumab is a VEGF neutralizing antibody
approved by the FDA for the treatment of cancers. This
ﬁnding supports the idea that VEGF plays a role in tumor
growthandalsosuggestsapossibletreatmentforhearingloss
in VS patients [96].
7. Novel Therapies in VS Treatment
Bevacizumab is the most studied agent of the new therapies
for vestibular schwannoma [16]. It consists of a humanized
monoclonal IgG1 antibody against VEGF. As previously
stated, vascular endothelial growth factors are associated
with tumor growth and therefore represent a new target in
VS therapy.
Recently, there has been increased attention to the audi-
tory beneﬁt registered in patients treated with Bevacizumab
[95, 97]. Mautner et al. [97] treated 2 patients, one for 3
months and one for 6 months. Improved hearing could be
registered in the patient treated for 6 months. The only
side eﬀect mentioned was high blood pressure in one of the
patients.
Plotkin et al. [95] reported the best auditory bene-
ﬁt described in the literature. They administered Beva-
cizumab to 7 patients, of whom 4 (57%) reported hearing
improvement. The results were evaluated on the basis of
the word recognition score (WRS). Patient number 2 had
the best result, with a WRS of 8% prior to therapy and
98% after therapy. Hearing improvement was sustained for
up to 16 months. The authors explained the improvement
in hearing as due to reduction of intraneural edema and
reduction in tumoral size. This conclusion was based on
the evolution of hearing loss, the correlation between the
mean apparent diﬀusion coeﬃcient (a measurement of the
magnitude of diﬀusion of water molecules within tissue and
a marker of edema on imaging MRI), tumor shrinkage, and
measurements (on a dynamic contrast MRI) of the changes
in intratumoral vascular permeability.
Both of these previous studies corroborated a reduction
in tumoral burden. In another study published in 2010
[98], the authors demonstrated that anti-VEGF therapy
normalizes vasculature in schwannoma xenografts in nude
mice and controls tumor growth. Vascular normalization in
benign tumors is an important issue when considering this
treatment. New anti-VEGF agents are being developed (e.g.,
PTC299), which have mitigation of hearing loss as a main
clinical outcome [16, 99].
Erlotinib is an oral EGFR tyrosine kinase inhibitor. Its
main target is the arresting of the proliferative properties of
the tumor. Plotkin et al. [100] evaluated 10 patients who
underwent treatment with Erlotinib. In three patients, the
disease was stable, as measured by radiographic evaluation.
Regarding their hearing outcomes, one patient presented
a transient hearing response, 2 experienced minor hearing
response (lasting 19 and 24 months), 3 patients were
stabilized, and 2 presented progressive hearing loss. The
authors commented that Erlotinib may have more cytostatic
properties as well as being less eﬀective in progressive
VS. More studies are needed with emphasis on time to
progression as an important outcome, rather than tumoral
volume or hearing status.
An in vitro study by Ammoun et al. [101] included
VS samples and identiﬁed overexpression and activation of
EGFR family receptors. They found that lapatinib inhibited
ErbB2 phosphorylation and downstream ERK1/2 and AKT
activation, resulting in decreased proliferation. Phase II
studies are pending.
Other pathways such as PAK inhibitors are under investi-
gation [99].
8. Conclusions
In this paper we describe some of the molecular mechanisms
involved in vestibular schwannoma development. The NF2
gene mutation, chromosome 22 loss, NF2 gene mitotic
recombination, DNA methylation, deregulation of genes,
immunogenic factors, cytokines, and growth factors are the
key to understand the molecular pathophysiology of VS.
Also, many theories have been advanced to explain
hearing loss associated with VS patients, but there is growing
evidence concerning molecular-based data. The methylation
of TP73, the negative expression of cyclin D1, the positive
expressionofB7-H1,increasedexpressionofplatelet-derived
growth factor A, underexpression of PEX5L, RAD54B, andGenetics Research International 7
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Figure 2: Available evidence of molecular mechanisms implicated
inVSpatientswithhearinglossPEX5L(peroxisomalbiogenesisfac-
tor 5-like gene), RAD54B (RAD54 homolog B), PSMAL (prostate-
speciﬁc membrane antigen-like), CEA (carcinoembryonic antigen),
PDGFA (platelet-derived growth factor A, B7-H1 (B7 homolog 1).
PSMAL, and overexpression of CEA are factors associated
with hearing loss and VS (Figure 2).
Noveltherapiesalsoconﬁrmthatmolecularinvestigation
could be a promising alternative for the treatment of VS.
More studies are needed to corroborate these results and,
more broadly, to establish links between molecular and
clinical data.
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